
On December 10, 2025, Viva Biotech hosted a Viva BioInsights webinar, themed “Adventures in DMPK: From Small Molecules and PROTACs to Peptides and Antibodies”. The session featured Dr. Justin Cui, Vice President in Pharmacology, and was moderated by Mr. Simon Bury, VP of Business Development.
Dr. Justin Cui:
Dr. Cui emphasized that Viva Biotech has established a comprehensive DMPK platform spanning multiple drug modalities, embedded within a one-stop service model that connects structure-based discovery with ADME, pharmacokinetics, pharmacology, toxicology, and IND filing—supporting more confident and data-driven development decisions throughout the preclinical stage.

Simon is a member of Viva's Global Business Development Team and is based in the UK.
He has worked in the life sciences industry for the past 25 years and is an experienced and well-networked business developer. Simon has worked for contract research organizations based in the US, UK, China and Australia providing a range of services spanning the entire drug discovery and development process including chemistry, biology, ADME-Tox and fully integrated drug discovery services.

Dr. Cui joined Viva in early 2024 as Vice President of Pharmacology. He previously served as Head of the Pharmacology Department at WuXi Biologics (2016–2024) and spent 9 years as a Senior Research Scientist at Pfizer/Wyeth. He earned his PhD in Immunology from Chiba University in 1998 and completed postdoctoral training at Harvard University.

For video replay,please provide the following details.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号